| Name | Title | Contact Details |
|---|
Evelo Biosciences is dedicated to improving the lives of patients globally through the development of a new modality of medicines – monoclonal microbials. Monoclonal microbials are orally delivered medicines that modulate systemic immunology and biology through direct interactions with human cells in the gut. These new medicines are broadly applicable across many diseases – including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory diseases and cancer. Monoclonal microbials have the potential to fundamentally change traditional models of drug discovery and development. By finding and selecting naturally occurring monoclonal microbials with defined therapeutic effects, Evelo can improve the speed, cost and success of drug discovery and development. Evelo`s platform enables pharmacological intervention at all stages of disease with naturally occurring, safe and effective monoclonal microbials. Evelo Biosciences was conceived and created within VentureLabs®, Flagship Pioneering`s institutional innovation foundry, and launched by Flagship in 2015.
Brain Corp is a software technology company specializing in the development of intelligent, autonomous systems. Brain Corp`s A.I. technology represents the next generation of artificial brains for self-driving vehicles (SDVs). We`re building brains for robots, and turning today`s manually-operated machines into tomorrow`s autonomous solutions.
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. Its full-stack, AI-powered drug discovery platform integrates modern technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science. We partner with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development.
NewNeural is a Naperville, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ValenzaBio is a privately-held biopharmaceutical company developing therapies for autoimmune and inflammatory diseases. With a pipeline of differentiated monoclonal antibodies targeting clinically-validated mechanisms of action, we seek to provide improved therapies for patients with limited treatment options. Based in Bethesda, Maryland, in the heart of the capital biotech community, we strive to work collaboratively with all stakeholders while keeping our research and development efforts focused on the needs of patients.